查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990214

燒燙傷軟膏市場：2026-2032年全球市場預測（按產品類型、活性成分、燒燙傷嚴重程度、最終用戶和分銷管道分類）

Burn Ointment Market by Product Type, Active Ingredient, Burn Degree, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，燒燙傷藥膏市場價值將達到 12.7 億美元，到 2026 年將成長到 13.5 億美元，到 2032 年將達到 20.2 億美元，複合年成長率為 6.84%。

主要市場統計數據
基準年 2025 12.7億美元
預計年份：2026年 13.5億美元
預測年份 2032 20.2億美元
複合年成長率 (%) 6.84%

權威概述了現代燒傷護理背後的驅動力，重點介紹了以臨床優先事項、監管壓力和創新為重點的治療模式。

燒傷治療已不再局限於簡單的傷口敷料，而是涵蓋了合理使用抗生素、再生醫學的進步以及以患者為中心、優先考慮功能恢復的護理模式。臨床醫師如今需要在快速上皮化、感染控制和減少疤痕之間取得平衡，而保險公司和採購團隊也越來越重視可證明的臨床價值。在此背景下，外用製劑、先進敷料和綜合護理路徑構成了現代燒傷管理策略的核心。

治療創新、分散式照護和數位化監測如何重塑燒傷管理的臨床實踐和商業策略？

燒傷治療領域正經歷著一場變革，其驅動力來自於技術進步、護理模式的轉變以及對抗生素抗藥性日益成長的擔憂。新型外用製劑和給藥系統強調標靶抗菌作用與組織保護特性的結合，這反映了整個產業從單純的對症治療轉向積極促進組織再生治療方法的轉變。同時，手術和非手術治療途徑正在融合，從而促進能夠同時支持住院治療和門診復健的綜合產品策略的形成。

促進供應鏈韌性、來源多元化以及商業和監管機構之間更緊密合作的新關稅措施的營運和策略影響。

2025年關稅措施的實施給整個國際供應鏈帶來了新的成本壓力，促使人們對局部用藥產品的採購、生產和分銷方式進行策略性重新評估。許多製造商面臨進口原料和成品成本增加的問題，進而影響了臨床領域的採購談判和庫存政策。採購團隊已採取措施，提高供應商成本結構的透明度，並探索替代採購方式以降低關稅風險。

按細分市場分類的臨床和商業性需求：揭示配方選擇、成分概況、醫療保健環境和分銷管道策略如何決定產品的採用和獲取。

基於細分市場的洞察揭示了不同產品類型、活性成分、燒燙傷嚴重程度、終端用戶環境和分銷管道所帶來的不同的治療和商業性動態，每種情況都需要量身定做的方法。每種劑型——乳膏、凝膠、軟膏和噴霧劑——在易用性、傷口停留時間和與繃帶的兼容性方面都具有獨特的優勢。因此，製劑研發人員必須最佳化流變特性和防腐體系，以適應臨床工作流程和看護者的能力。在活性成分方面，蘆薈、生長因子、蜂蜜、銀奈米顆粒和磺胺嘧啶銀的作用機制、安全性考量和實證依據有顯著差異，這會影響臨床應用和處方集納入決策。

臨床實務法規和供應鏈能力的區域差異，需要製定本地化的產品和打入市場策略。

區域趨勢對臨床實踐、法律規範和供應策略有顯著影響，因此產品開發和市場准入需要採取在地化策略。在美洲，臨床網路強調快速獲得急診和健全的醫院採購系統，這為那些已被證實能夠減少併發症和縮短住院時間的產品創造了機會。相較之下，在歐洲、中東和非洲，不同的管理體制和異質的報銷環境則要求採用模組化的市場策略，優先考慮合規性和有針對性的臨床夥伴關係。

我們的競爭優勢源自於已證實的臨床療效、強大的生產能力和一體化的商業服務，這些都使我們的產品在整個護理過程中發揮了價值。

燒燙傷藥膏市場的競爭優勢取決於臨床證據、生產可靠性和商業性彈性的綜合運用。主要企業透過專注於臨床檢驗、完善的品質體係以及能夠處理標準配方和特殊配方的靈活生產來脫穎而出。與學術機構和專業燒燙傷治療部門建立策略合作夥伴關係，可以進一步提高可靠性並加速真實世界臨床證據的累積。此外，整合數位化傷口評估工具和護理教育平台的夥伴關係，能夠拓展產品價值，使其超越活性成分本身。

為產品領導者提供切實可行的策略措施，以協調臨床證據、生產柔軟性和通路特定的商業化，從而建立永續的競爭優勢。

產業領導者應採取多管齊下的方法，平衡證據產生、供應鏈韌性和可操作的商業性實施，將洞察轉化為可衡量的成果。首先，優先進行針對特定燒傷程度和護理環境下活性成分對比的臨床試驗，以產生可用於藥品目錄納入和臨床指南制定的可操作證據。其次，投資於靈活的生產結構和多元化的供應商，以降低貿易中斷和關稅波動帶來的風險，確保為需要高級治療的醫療機構和居家照護項目提供穩定的產品供應。

嚴謹的混合方法，結合臨床證據、專家檢驗和供應鏈分析，能夠產生可操作且可靠的見解。

這些研究結果是基於對同儕審查的臨床文獻、監管指南和真實世界臨床模式的系統性回顧，並輔以對臨床醫生、採購專家和供應鏈管理人員的結構化訪談。在整合證據時，優先考慮高品質的隨機對照試驗、療效比較研究和臨床指南，以確保建議反映共識和新興的最佳實踐。在缺乏可靠試驗數據的情況下，分析中納入了對活性成分作用機制的理解以及經驗豐富的燒傷護理人員的實務經驗。

透過強調實證產品開發和強大的商業化，我們可以透過綜合結論來改善患者療效和業務績效。

總之，最佳化燒傷治療需要整合臨床療效、營運韌性和市場導向的商業化策略。活性成分和劑型的創新雖然拓展了治療的可能性，但臨床應用取決於可靠的證據、便利的使用方法和值得信賴的供應鏈。隨著治療逐漸轉向門診和家庭環境，生產者和醫療保健系統必須通力合作，確保產品在傳統醫院環境之外仍能保持安全、有效和可近性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：燒燙傷藥膏市場：依產品類型分類

  • 奶油
  • 凝膠
  • 軟膏
  • 噴

第9章：以活性成分分類的燒燙傷軟膏市場

  • 蘆薈
  • 生長因子
  • 蜂蜜
  • 銀奈米粒子
  • 磺胺嘧啶銀

第10章：依燒燙傷嚴重程度分類的燒燙傷藥膏市場

  • 一度燒傷
  • 二度燒傷
  • 三度燒傷

第11章：燒燙傷藥膏市場：以最終用戶分類

  • 門診手術中心
  • 燒傷中心
  • 居家照護
  • 醫院和診所

第12章：燒燙傷藥膏市場：依分銷管道分類

  • 醫院藥房
  • 網路商店
  • 零售藥房

第13章：燒燙傷藥膏市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：燒燙傷膏市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：燒燙傷藥膏市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國燒燙傷藥膏市場

第17章：中國燒燙傷藥膏市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Advancis Medical
  • B. Braun SE
  • Cardinal Health, Inc.
  • Cipla Limited
  • Coloplast A/S
  • ConvaTec Group PLC
  • DeRoyal Industries Inc.
  • Dr. Morepen
  • Gentell
  • GlaxoSmithKline PLC
  • Hollister Incorporated
  • Intergra LifeSciences
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Maxingvest AG
  • McKesson Corporation
  • Medline Industries, LP
  • Milliken & Company
  • Molnlycke Health Care AB
  • Otsuka Pharmaceutical Co., Ltd.
  • Paul Hartmann AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Smith & Nephew PLC
  • Sun Pharmaceutical Industries Ltd.
  • Trio Lifescience Pvt. Ltd.
Product Code: MRR-99555D55052F

The Burn Ointment Market was valued at USD 1.27 billion in 2025 and is projected to grow to USD 1.35 billion in 2026, with a CAGR of 6.84%, reaching USD 2.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.27 billion
Estimated Year [2026] USD 1.35 billion
Forecast Year [2032] USD 2.02 billion
CAGR (%) 6.84%

An authoritative overview of contemporary burn care drivers highlighting clinical priorities regulatory pressures and innovation-focused treatment paradigms

Burn treatment has evolved beyond simple wound coverage to encompass antimicrobial stewardship, regenerative medicine advances, and patient-centered care models that prioritize functional recovery. Clinicians now balance rapid re-epithelialization with infection control and scar mitigation, while payers and procurement teams increasingly demand demonstrable clinical value. Against this backdrop, topical formulations, advanced dressings, and integrated care pathways constitute the core of modern burn management strategies.

In parallel, innovation in active ingredients and delivery formats has expanded therapeutic options. Manufacturers and clinicians are integrating biologically active compounds, silver-based antimicrobials, and naturally derived agents into products that aim to reduce healing time and minimize complications. As a result, decision-makers must weigh clinical efficacy, safety profiles, and supply continuity when selecting products for acute care centers, ambulatory surgical settings, and home-based recovery programs. Furthermore, regulatory scrutiny and evolving reimbursement dynamics are shaping product development and commercialization strategies, creating both constraints and opportunities for stakeholders seeking to differentiate on clinical evidence and practical utility.

Consequently, strategic planning for burn care requires a holistic view that reconciles clinical priorities, procurement realities, and emerging scientific evidence to ensure interventions deliver measurable improvements in patient outcomes and system-level efficiencies.

How therapeutic innovation decentralization of care and digital-enabled monitoring are reshaping clinical practice and commercial strategies in burn management

The burn care landscape is undergoing transformative shifts driven by technological advances, changing care delivery models, and heightened focus on antimicrobial resistance. New topical agents and delivery systems emphasize targeted antimicrobial activity combined with tissue-preserving properties, reflecting an industry-wide pivot from purely symptomatic care to therapies that actively support regeneration. At the same time, surgical and non-surgical management pathways are converging, encouraging integrated product strategies that can support both inpatient procedures and outpatient rehabilitation.

Meanwhile, care delivery is decentralizing as many interventions migrate from tertiary burn centers to ambulatory surgical centers and homecare settings. This transition stresses the need for formulations that are easy to apply, stable under variable storage conditions, and safe for non-specialist caregivers. Simultaneously, digital health tools and telemedicine consultations are augmenting clinical oversight, enabling remote monitoring of wound healing and reducing unnecessary clinic visits. These shifts create new expectations for manufacturers to provide not only effective products but also education, adherence support, and digital resources that facilitate remote care.

Taken together, these trends drive a more patient-centric, cost-aware, and evidence-driven market environment where agility, cross-functional collaboration, and a clear value proposition determine commercial success.

The operational and strategic consequences of new tariff measures driving supply chain resilience sourcing diversification and closer commercial-regulatory collaboration

The implementation of tariff measures in 2025 enforced new cost pressures across international supply chains and prompted a strategic reassessment of sourcing, manufacturing, and distribution practices for medical topical agents. Many manufacturers faced increased landed costs for imported raw materials and finished goods, which in turn affected procurement negotiations and inventory policies across clinical settings. Procurement teams responded by seeking greater transparency in supplier cost structures and by exploring alternative sourcing arrangements that reduce tariff exposure.

Consequently, supply chain resilience became a priority, with manufacturers accelerating qualification of secondary suppliers, enlarging safety stocks for critical inputs, and evaluating nearshoring options to mitigate future trade disruptions. At the same time, regulatory compliance and customs administration complexities increased transaction lead times, particularly for specialty active ingredients that require stringent handling. These operational frictions incentivized stronger supplier partnerships and more frequent cross-functional planning between commercial, regulatory, and operations teams.

Ultimately, the cumulative impact of tariff changes reinforced the importance of flexible manufacturing footprints and diversified procurement strategies. Stakeholders that proactively redesigned supply chains and negotiated value-based contracts were better positioned to preserve clinical access and maintain commercial momentum despite cost headwinds.

Segment-specific clinical and commercial imperatives exposing how formulation choices ingredient profiles care settings and channel strategies determine adoption and access

Segmentation-driven insight reveals distinct therapeutic and commercial dynamics across product types, active ingredients, burn degrees, end-user settings, and distribution channels that require tailored approaches. Cream, gel, ointment, and spray formats each present unique advantages related to ease of application, residence time on the wound, and compatibility with dressings; consequently, formulators must optimize rheology and preservative systems to align with clinical workflows and caregiver capabilities. In terms of active agents, aloe vera, growth factors, honey, silver nanoparticles, and silver sulfadiazine differ considerably in mechanism of action, safety considerations, and evidence base, which impacts clinical adoption and formulary decisions.

Burn degree stratification is clinically consequential: first degree, second degree, and third degree injuries demand different therapeutic priorities, ranging from symptomatic relief and infection prophylaxis to advanced regenerative interventions and surgical adjuncts. End-user segments such as ambulatory surgical centers, burn centers, homecare environments, and hospitals and clinics impose varied specifications for product robustness, packaging, and instructional support. Distribution channels further influence product positioning and access; hospital pharmacies, online stores, and retail pharmacies each require distinct commercialization strategies, pricing models, and regulatory documentation to satisfy procurement and consumer expectations.

Therefore, companies must align formulation strategy, clinical evidence generation, and channel management with the nuances of each segment to optimize uptake and ensure products meet the practical needs of clinicians and caregivers across diverse care settings.

How geographic variations in clinical practice regulation and supply chain capabilities necessitate regionally tailored product and market entry strategies

Regional dynamics exert a pronounced influence on clinical practice, regulatory frameworks, and supply strategies, necessitating geographically informed approaches to product development and market entry. In the Americas, clinical networks emphasize rapid access to acute care and robust hospital procurement systems, which create opportunities for products demonstrated to reduce complications and shorten facility stays. Conversely, in Europe, Middle East & Africa, varying regulatory regimes and heterogeneous reimbursement environments encourage modular market strategies that prioritize regulatory alignment and targeted clinical partnerships.

Asia-Pacific presents a diverse mix of advanced tertiary centers and expanding community healthcare capacity, alongside strong manufacturing bases for active ingredients and finished goods. This region often balances high-volume procurement needs with localized clinical preferences and growing demand for both advanced antimicrobials and cost-effective natural alternatives. Across these geographies, differences in patient demographics, scar prevention priorities, and healthcare delivery models shape product acceptance and required evidence packages. Consequently, stakeholders must calibrate clinical trial designs, regulatory submissions, and go-to-market tactics to reflect regional practice patterns and procurement expectations.

In sum, nuanced regional strategies that acknowledge regulatory complexity, supply chain realities, and local clinical priorities yield better patient outcomes and enhance commercial viability across global footprints.

Competitive advantage stems from clinical validation manufacturing resilience and integrated commercial services that extend product value across care pathways

Competitive positioning in the burn ointment arena depends on a blend of clinical evidence, manufacturing reliability, and commercial agility. Leading companies differentiate through focused investment in clinical validation, robust quality systems, and agile manufacturing that accommodates both standard and specialized formulations. Strategic collaborations with academic centers and specialized burn units further strengthen credibility and accelerate real-world evidence generation. In addition, partnerships that integrate digital wound assessment tools or nurse education platforms amplify product value beyond the active compound alone.

Operational excellence is equally important; firms that maintain diversified sourcing and responsive production capacity reduce supply risk and support sustained clinical adoption. Commercially, companies that offer comprehensive supplier services-ranging from training for clinicians to patient education and adherence support-achieve deeper penetration across hospitals, ambulatory surgical centers, and homecare channels. Similarly, flexibility in packaging sizes and formats addresses the varying needs of institutional buyers and retail consumers, improving inventory turnover and lowering waste.

By combining rigorous clinical programs with resilient operations and value-added services, organizations can secure a defensible market position and create pathways for long-term growth despite intensifying competition and evolving care models.

Practical strategic measures for product leaders to align clinical evidence manufacturing flexibility and channel-specific commercialization for sustainable advantage

Industry leaders should adopt a multi-pronged approach that balances evidence generation, supply chain resilience, and pragmatic commercial execution to convert insights into measurable outcomes. First, prioritize targeted clinical studies that compare active ingredients in the contexts of specific burn degrees and care settings to generate actionable evidence for formulary inclusion and clinical guidelines. Second, invest in flexible manufacturing and supplier diversification to reduce exposure to trade disruptions and tariff volatility, thereby safeguarding product availability for high-acuity centers and homecare programs.

Third, develop differentiated go-to-market models that account for channel-specific needs, including hospital pharmacy purchasing behaviors and consumer purchasing via online stores and retail pharmacies. Fourth, integrate clinician education and digital support tools to facilitate appropriate product usage in ambulatory and homecare environments, which will improve adherence and clinical outcomes. Fifth, pursue regionally tailored regulatory strategies that reflect local practice patterns and reimbursement pathways, enabling faster adoption in diverse geographies while ensuring compliance.

Taken together, these actions create a coherent strategy that aligns clinical credibility with operational sturdiness and commercial relevance, positioning companies to capture value while improving patient care.

A rigorous mixed-methods approach combining clinical evidence synthesis expert validation and supply chain analysis to produce actionable and reliable insights

The research underpinning these insights combined a systematic review of peer-reviewed clinical literature, regulatory guidance, and real-world practice patterns, supplemented by structured interviews with clinicians, procurement specialists, and supply chain managers. Evidence synthesis prioritized high-quality randomized trials, comparative effectiveness studies, and clinical guidelines to ensure recommendations reflect consensus and emerging best practice. Where robust trial data were limited, the analysis incorporated mechanistic understanding of active ingredients and practical considerations from experienced burn care providers.

In addition, the study assessed supply chain and policy developments by reviewing tariff schedules, customs processes, and manufacturing capacity reports to evaluate operational implications. Cross-validation occurred through expert panels and clinician workshops that evaluated the practical applicability of recommendations across different care settings. Throughout, the methodology emphasized triangulation of sources to mitigate bias and ensure findings are actionable for commercial and clinical stakeholders. Finally, ethical considerations and patient safety remained central to evaluating therapeutic options, with attention to adverse event profiles and safety monitoring requirements necessary for clinical deployment.

Integrated conclusions that emphasize evidence-led product development and resilient commercialization to improve patient outcomes and business performance

In conclusion, optimizing burn care requires integrated strategies that marry clinical efficacy with operational resilience and market-aware commercialization. Innovations in active ingredients and delivery formats are expanding therapeutic possibilities, but clinical adoption depends on credible evidence, practical usability, and dependable supply chains. As care shifts toward ambulatory and home-based settings, manufacturers and health systems must collaborate to ensure products are safe, effective, and accessible outside traditional hospital environments.

Moreover, trade dynamics and regulatory variation underscore the need for flexible sourcing and region-specific planning. Organizations that proactively invest in diverse supplier networks, targeted clinical programs, and tailored channel strategies will be better positioned to navigate uncertainty while delivering measurable improvements in patient outcomes. Ultimately, the intersection of science, logistics, and market intelligence will determine which products achieve lasting clinical impact and commercial success. Stakeholders that act decisively on these integrated imperatives can drive better care for patients with burn injuries while creating sustainable value for their organizations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Burn Ointment Market, by Product Type

  • 8.1. Cream
  • 8.2. Gel
  • 8.3. Ointment
  • 8.4. Spray

9. Burn Ointment Market, by Active Ingredient

  • 9.1. Aloe Vera
  • 9.2. Growth Factors
  • 9.3. Honey
  • 9.4. Silver Nanoparticles
  • 9.5. Silver Sulfadiazine

10. Burn Ointment Market, by Burn Degree

  • 10.1. First Degree Burns
  • 10.2. Second Degree Burns
  • 10.3. Third Degree Burns

11. Burn Ointment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Burn Centers
  • 11.3. Homecare
  • 11.4. Hospitals Clinics

12. Burn Ointment Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Stores
  • 12.3. Retail Pharmacies

13. Burn Ointment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Burn Ointment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Burn Ointment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Burn Ointment Market

17. China Burn Ointment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3M Company
  • 18.6. Advancis Medical
  • 18.7. B. Braun SE
  • 18.8. Cardinal Health, Inc.
  • 18.9. Cipla Limited
  • 18.10. Coloplast A/S
  • 18.11. ConvaTec Group PLC
  • 18.12. DeRoyal Industries Inc.
  • 18.13. Dr. Morepen
  • 18.14. Gentell
  • 18.15. GlaxoSmithKline PLC
  • 18.16. Hollister Incorporated
  • 18.17. Intergra LifeSciences
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Mankind Pharma Ltd.
  • 18.20. Maxingvest AG
  • 18.21. McKesson Corporation
  • 18.22. Medline Industries, LP
  • 18.23. Milliken & Company
  • 18.24. Molnlycke Health Care AB
  • 18.25. Otsuka Pharmaceutical Co., Ltd.
  • 18.26. Paul Hartmann AG
  • 18.27. Perrigo Company PLC
  • 18.28. Pfizer Inc.
  • 18.29. Smith & Nephew PLC
  • 18.30. Sun Pharmaceutical Industries Ltd.
  • 18.31. Trio Lifescience Pvt. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BURN OINTMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BURN OINTMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BURN OINTMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BURN OINTMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BURN OINTMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BURN OINTMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BURN OINTMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BURN OINTMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BURN OINTMENT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BURN OINTMENT MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BURN OINTMENT MARKET SIZE, BY ALOE VERA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BURN OINTMENT MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BURN OINTMENT MARKET SIZE, BY HONEY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BURN OINTMENT MARKET SIZE, BY SILVER SULFADIAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BURN OINTMENT MARKET SIZE, BY FIRST DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BURN OINTMENT MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BURN OINTMENT MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BURN OINTMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BURN OINTMENT MARKET SIZE, BY BURN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BURN OINTMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITALS CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BURN OINTMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BURN OINTMENT MARKET SIZE, BY ONLINE STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BURN OINTMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BURN OINTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BURN OINTMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BURN OINTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GCC BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GCC BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. G7 BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 141. G7 BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 142. G7 BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. G7 BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BURN OINTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA BURN OINTMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA BURN OINTMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA BURN OINTMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA BURN OINTMENT MARKET SIZE, BY BURN DEGREE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA BURN OINTMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA BURN OINTMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)